OC
AQST icon

Oppenheimer & Co’s Aquestive Therapeutics AQST Stock Holding History

Oppenheimer & Co’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Buy
+37,885
New +$154K ﹤0.01% 1604
2025
Q4 		– Sell
-33,532
Closed -$187K – 1561
2025
Q3 		$187K Buy
+33,532
New +$145K ﹤0.01% 1556

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Oppenheimer & Co's AQST Position: Q1 2026 in Review

Oppenheimer & Co opened a new position in Aquestive Therapeutics (AQST) in Q1 2026: 37,885 shares worth $157K. The stake represents ﹤0.01% of the portfolio and ranks #1604 among its holdings. This is a return to the name: Oppenheimer & Co previously reported a position in AQST as recently as Q3 2025.

Oppenheimer & Co first reported a position in AQST in Q3 2025 and has held it in 2 quarters since. The position peaked at $187K in Q3 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Oppenheimer & Co held 37,885 shares of Aquestive Therapeutics worth $157K as of Q1 2026.
  • Aquestive Therapeutics was a new Oppenheimer & Co position in Q1 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1604 holding.
  • Oppenheimer & Co first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Oppenheimer & Co's Aquestive Therapeutics position peaked at $187K in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.